In high-income countries, antiretroviral therapy (ART) has led to a significant decrease in morbidity and mortality in patients infected with HIV [1,2]; however, ART is often associated with short-term and long-term adverse events that can lead to poor adherence and drug resistance. These obstacles motivated several randomized trials to assess the use of structured treatment interruptions (STI) to prevent ART toxicity, while
Introduction
maintaining the same efficacy as continuous treatment [3, 4] . Two randomized STI trials conducted in subSaharan Africa [4, 5] assessed outcomes in settings with higher rates of early HIV-related morbidity than in resource-rich countries [3, 6, 7] .
STI strategies can be guided either by individual CD4 + T-cell count or by time on therapy. Recent studies investigating CD4 + T-cell-guided STI, both outside of Africa (SMART) [3] and within Africa (Trivacan) [4] , were designed to interrupt ART at CD4 + T-cell counts >350 cells/µl and restart ART when CD4 + T-cell counts dropped to <250 cells/µl. Both trials were stopped early because of evidence that patients on STI were at a significantly higher risk of severe clinical events and death compared with continuous ART [3, 4] . However, it is unclear from these studies whether STI would have shown better results if different CD4 + T-cell-guided strategies had been examined [3, [8] [9] [10] .Moving forward, new clinical trials aimed at assessing alternative interruption/reintroduction thresholds would be time consuming and expensive, and could be considered unethical, given the results of the SMART and Trivacan trials [3, 4] . Our objective was to use a simulation model to assess different plausible STI strategies compared with continuous ART in Côte d'Ivoire, West Africa.
Methods

Analytical overview
Using a computer-based simulation model of HIV disease and treatment, we investigated the effect of different CD4 + T-cell-guided STI strategies on outcomes in HIV-infected patients in Côte d'Ivoire [11] [12] [13] [14] [15] . We evaluated HIV treatment strategies for three hypothetical cohorts of patients who presented to care with CD4 + T-cell counts ≤200 cells/µl, 201-350 cells/µl and 351-500 cells/µl. For each of these cohorts, we assessed three aspects of care: ART initiation criteria (immediate, CD4 + T-cell count <350 cells/µl or ≥350 cells/µl with severe HIV-related disease, and CD4 + T-cell count <200 cells/µl or ≥200 cells/µl with severe HIV-related disease); CD4 + T-cell count thresholds for interrupting ART (350 cells/µl, 500 cells/µl and 700 cells/µl); and CD4 + T-cell count thresholds for reintroducing ART after CD4 + T-cell decreased during interruptions (250 cells/µl, 350 cells/µl and 500 cells/µl; Table 1 ). We also projected outcomes for patients who remained on continuous treatment after initiating ART. We compared outcomes of STI and continuous ART in patients with similar CD4 + T-cell counts at presentation and ART initiation. The primary outcome of the analysis was life expectancy, measured in life-months. We also assessed costs in 2007 USD, from model entry until death. We adopted a modified societal perspective, excluding patient time and travel in our estimation of costs. We report undiscounted life expectancies, as well as life expectancies and costs discounted at 3% per year [16] .
Model overview
The Cost-Effectiveness of Preventing AIDS Complications (CEPAC) International model is a first-order state-transition Monte Carlo simulation of the natural history, clinical management, outcomes and costs of HIV disease [11, 12, 15] . The model simulates HIV disease in several resource-limited settings, including Côte d'Ivoire. Monthly transitions between 'health states' describe the natural history of disease. True CD4 + T-cell count, HIV RNA level and history of HIV-related conditions determine disease progression. Death can be attributed to an acute HIV-related disease, HIV infection itself or non-HIV-related causes. Other model specifications have been published elsewhere in detail [12, 15] .
For this analysis, we designed a new structural module to simulate STI. In this module, ART was interrupted and reintroduced according to predefined CD4 Table 1 . Strategies evaluated in a simulation of structured treatment interruption trials a Only applicable to the structured treatment interruption arm.
b We did not evaluate strategies with interruption CD4 + T-cell thresholds >700 cells/µl in these patients because the proportion of patients who reached this CD4 + T-cell count was small (37%), as shown in previous studies [25, 26] . ART, antiretroviral therapy.
and reintroductions alternated until patients reached an STI end point or died. STI end points were defined as one severe HIV-related disease event or CD4 + T-cell count decrease to <200 cells/µl, as in Trivacan [4] .
Simulated strategies
We considered two consecutive ART regimens, as per current standard-of-care in Côte d'Ivoire. First-line therapy was non-nucleoside reverse transcriptase inhibitor (NNRTI)-based and second-line was protease inhibitor (PI)-based [4, 17] . Clinic visits and CD4 + T-cell tests occurred every 2 months. We assumed that HIV RNA tests were not available for monitoring or decision making because they are not routinely available in Côte d'Ivoire and many other resource-limited settings; however, true CD4 + T-cell count and HIV RNA level both determined disease progression, as the model tracks clinical, immunological and virological status monthly.
We evaluated strategies separately for patients presenting to care with CD4 + T-cell counts ≤200 cells/µl, 201-350 cells/µl or 351-500 cells/µl. All patients who initiated care received cotrimoxazole. When patients became eligible for ART, they initiated treatment with continuous therapy (run-in period; Figure 1 ). Patients who failed first-line therapy or who never reached the threshold for interruption were considered to be ineligible for STI [4] . These patients switched to second-line therapy upon failing first-line therapy. When patients in the STI strategy were suppressed on first-line ART and reached the predefined CD4 + T-cell threshold for interruption, they were taken off therapy. They remained off ART until they reached the CD4 + T-cell threshold for reintroduction. They continued to cycle on and off first-line therapy until they reached any of three STI end points: observed CD4 + T-cell count <200 cells/µl during an interruption, when the CD4 + T-cell threshold for reintroducing ART was 250 cells/µl; one severe HIV-related disease event; or observed CD4 + T-cell count decrease to <200 cells/µl while on ART, a proxy for virological failure as HIV RNA tests were not available [4] . When the CD4 + T-cell threshold for reintroducing ART was 350 cells/µl or 500 cells/µl, patients could only reach the second and third end points, because the frequency of CD4 + T-cell tests prevented them from reaching <200 cells/µl during interruptions. After reaching an STI end point, patients resumed first-line NNRTI-based therapy without any new interruptions (Figure 1 ). Virological suppression rates differed depending on the STI end point reached.
Patients switched to a second-line PI-based regimen according to the main World Health Organization (WHO) clinical and immunological criteria for failure: an observed 50% decrease from peak on-treatment CD4 + T-cell count or a new severe HIV-related disease ( Figure 1 ) [18] .
Input data
Input parameters are summarized in Table 2 .
Cohort characteristics
The demographics of simulated patients matched the Trivacan trial [4] . Mean ±sd age was 35 ±8 years and 21% of patients were men. At baseline, 47% of patients had HIV RNA>100,000 copies/ml. We simulated three different strata for initial CD4 + T-cell counts, as described above.
Progression of HIV disease CD4
+ T-cell-stratified mortality and incidence of HIVrelated conditions, including AIDS and severe non-AIDS diseases, were from the Cotrame (ANRS 1203) and Primo-CI (ANRS 1220) cohort studies [6, 7] . Mortality and incidence rates were the same for patients in the STI arm and patients in the continuous ART arm who were off ART, either before initiating therapy or during interruptions. In the absence of data from Côte d'Ivoire, we used data reported by the Multicenter AIDS Cohort Study in the US to model monthly decreases in CD4 + T-cell count before ART initiation [19] . CD4 + T-cell decreases during ART interruptions and increases after ART reintroductions were from the CD4 + T-cell-guided STI arm of the Trivacan trial (Table 2 ) [4] .
Efficacy of ART
The efficacy of continuous NNRTI-based first-line ART was derived from Trivacan, in which 87% of patients achieved HIV RNA<300 copies/ml at 6 months [17] and 0.18% had virological failure each month thereafter [20] . The mean CD4 + T-cell count increase at 12 months was 152 cells/µl [20, 21] .
When patients in the STI strategy resumed continuous treatment, we considered NNRTI-based ART to be ineffective if they ended STI because their CD4 + T-cell counts decreased to <200 cells/µl while on ART. We assumed that these patients had virological failure and had developed resistance to NNRTIs. If patients ended STI because their CD4 + T-cell counts decreased to <200 cells/µl during an interruption or because of a severe HIV-related event, NNRTI-based continuous ART was less effective, to account for the increased resistance attributable to STI [4, 20] . In these patients, the probability of failing to achieve HIV RNA levels <300 copies/ml on NNRTI-based ART after ending STI was defined as the risk of resistance attributable to each interruption (4 per 100 personinterruptions) multiplied by the number of interruptions, plus the monthly probability of virological failure on ART (0.18%) [20] . For example, a patient who ended STI after three interruptions and was on ART for 12 months during STI was estimated to have an 85.8% (=100%-[4%×3]-[0.18%×12]) probability of becoming virologically suppressed upon resuming NNRTI-based ART.
We assumed that efficacy of second-line ART was the same as first-line ART because patients received one new drug class (PI) and two new nucleoside reverse transcriptase inhibitors (NRTIs) [17] . ART was considered to have a protective effect on severe morbidity and mortality independent of CD4 + T-cell count [22, 23] . We assumed that ART led to no fatal toxicity events. We tested this assumption in sensitivity analyses.
Costs
We estimated costs of routine medical care in Côte d'Ivoire, including laboratory tests, clinic visits, hospital stays and treatment of acute HIV-related diseases and toxicities. These costs have been reported elsewhere [12, 15] . 
Sensitivity analyses
We performed extensive sensitivity analyses on major model parameters. Specifically, we evaluated the implications of alternative assumptions in areas lacking primary data, including CD4 + T-cell changes for patients interrupting and reintroducing ART at CD4 + T-cell counts higher than in Trivacan, the proportion of patients reaching each STI end point, and second-line ART efficacy. We assessed the effect of using PI-based ART during STI by reducing the risk of resistance to ART after returning to continuous treatment, as well as the effect of variations in the rate of fatal toxicity caused by ART and increased rates of morbidity during interruptions. We also varied region-specific parameters, such as the incidence of various HIV-related diseases and the probability of acquiring severe non-AIDS a >100,000 copies/ml, % 47.0 -30,001-100,000 copies/ml, % 24.5 -10,001-30,000 copies/ml, % 15.1 -3,001-10,000 copies/ml, % 6.6 -501-3,000 copies/ml, % 2.5 -≤500 copies/ml, % 4.4 -Efficacy of continuous first-line NNRTI-based ART and second-line PI-based ART HIV RNA<300 copies/ml at 6 months, % a These estimates were from primary data subanalyses that were performed to derive model parameters, and were not published in the cited reference. b Effect was found for and applies to all severe HIV-related diseases except for tuberculosis [22] . We used the lowest prices available from generic or brand manufacturers in the 2008 Médecins Sans Frontières report [45] . AD, assumed distribution; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; LPV/r, lopinavir/ritonavir, NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; STI, structured treatment interruptions; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.
conditions during interruptions, in order to account for the increased risk of malignancies and cardiovascular diseases observed in the SMART trial [3, [8] [9] [10] 24] . Finally, we considered longer intervals between clinic visits and CD4 + T-cell tests in order to account for potential variability in access to care.
Results
Model validation
We performed an internal validation analysis of our model by matching the mean CD4 + T-cell counts over time of the simulated cohorts with data from the continuous ART and STI arms of the Trivacan trial. Model projections of CD4 + T-cell counts were within 2% of reported trial results at 12 months and within 8% at 24 months (Supplementary Figure 2 , Additional file 1).
Base case analyses
In a cohort of patients presenting to care with CD4 + T-cell counts ≤200 cells/µl (mean ±sd, 100 ±51 cells/µl) and starting ART immediately, STI was always less effective than continuous ART, regardless of interruption/reintroduction CD4 + T-cell thresholds (Table 3 ) [25, 26] . STI reduced undiscounted life expectancy by 11-48 months compared with continuous ART, depending on the interruption/reintroduction CD4 + T-cell threshold. In a cohort of patients presenting to care with CD4 T-cell-guided STI was less effective or comparable to continuous treatment, depending on ART initiation criteria and interruption/reintroduction CD4 + T-cell thresholds (Table 3) . When we replicated the 350/250 cells/ µl interruption/reintroduction strategy of the Trivacan trial, STI resulted in mean undiscounted life expectancies 59-69 months lower than continuous ART, depending on CD4 + T-cell count at presentation and ART initiation criteria. Patients who interrupted/reintroduced ART at CD4 + T-cell 700/500 cells/µl had mean life expectancies between 2 months lower and 1 month higher than patients on continuous ART. Patients who presented to care with CD4 + T-cell counts 201-350 cells/µl or >350 cells/µl, started ART immediately and interrupted/reintroduced therapy at CD4 + T-cell 700/500 cells/µl interrupted ART a mean ±sd of 4 ±3 times, with interruptions lasting an average of 18 months. In both groups, patients spent 79% of their time on ART and 21% of their time off ART after entering the model. Figure 2 shows model-generated survival curves for patients starting ART immediately and presenting to care with CD4 + T-cell counts 201-350 cells/µl ( Figure  2A ) or 351-500 cells/µl ( Figure 2B ). STI and continuous ART produced similar life expectancies in the first 2 years, but long-term projections from entry into the model until death suggest that continuous ART is better than STI in almost all cases. Long-term life expectancy estimates for STI were only comparable to continuous ART when patients interrupted ART at CD4 + T-cell counts >700 cells/µl and reintroduced ART at CD4 + T-cell counts <500 cells/µl.
STI was always associated with lower costs than continuous ART (Table 3) . When patients presented to care with CD4 + T-cell counts 201-350 cells/µl, initiated ART immediately, interrupted ART at CD4 + T-cell counts >700 cells/µl and reintroduced ART at CD4 + T-cell counts <500 cells/µl, per person lifetime costs were USD 2,200 lower than for continuous ART.
Sensitivity analyses
We performed sensitivity analyses on patients with initial CD4 + T-cell counts of 201-350 cells/µl and >350 cells/µl who started ART immediately and interrupted/reintroduced therapy at CD4 + T-cell counts 700/500 cells/µl. Results were most sensitive to variations in the rate of ART-related fatal toxicity and the risk of resistance to ART after each interruption. If we assumed that the yearly rate of fatal ART toxicity was 0.6/100 person-years, based on reported rates of NNRTI-related fatal lactic acidosis in sub-Saharan Africa [27, 28] , STI increased life expectancy by 5 months in patients with initial CD4 + T-cell counts of 201-350 cells/µl and 4 months in patients with initial CD4 + T-cell counts >350 cells/µl. When interrupting ART did not cause additional resistance compared with continuous ART, as might be the case if PI-based ART were used for the initial regimen, STI increased life expectancy by 11 and 15 months in each group. In this case, STI became cost-saving compared with continuous treatment.
Results were less sensitive to variations in rates of severe non-AIDS diseases during STI, the overall incidence of HIV-related diseases, morbidity events while on ART and the frequency of CD4 + T-cell tests. Detailed results of these sensitivity analyses can be found in Supplementary Table 2 and Supplementary Figure 2 (Additional file 1). Our results were robust to wide variations in all parameters for which primary data were not available. These included CD4 + T-cell changes for higher interruption/reintroduction thresholds than in Trivacan; the proportion of patients reaching each STI end point when interruption/reintroduction thresholds were higher; and efficacy of second-line ART (Additional file 1).
Discussion
Interest in CD4
+ T-cell-guided STI has increased, with studies suggesting that it could decrease ART-related toxicity and costs [29] [30] [31] [32] [33] . However, two recent randomized trials (SMART and Trivacan) found that STI was associated with higher AIDS and severe non-AIDS morbidity and mortality [3, 4, 9, 20, 34] . In these studies patients interrupted ART at CD4 + T-cell counts >350 cells/µl and restarted ART at CD4 + T-cell counts <250 cells/µl.
Although STI could be attractive at different thresholds for interruption and reintroduction, new STI trials are unlikely. Drawing on data from previous trials, we used a simulation model to evaluate the short-and long-term outcomes of alternative STI strategies in Côte d'Ivoire. We simulated patients with different CD4 + T-cell counts at presentation to care, ART initiation, interruption and reintroduction. In almost all cases, STI was less effective than continuous ART, but differences Table 3 . Projected outcomes of structured treatment interruptions and continuous ART in Côte d'Ivoire a We did not evaluate strategies with interruption CD4 + T-cell thresholds >700 cells/µl in these patients because the proportion of patients who reached this CD4 + T-cell count was small (37%), as shown in previous studies [25, 26] in life expectancy between STI and continuous ART decreased with increasing thresholds. Patients on STI had life expectancies closest to continuous ART when they presented to care with CD4 + T-cell counts >200/ µl, initiated ART immediately and interrupted/reintroduced ART at very high CD4 + T-cell counts (700/500 cells/µl). The number and duration of interruptions was highly variable, however, suggesting that a strategy of fixed-time STI would not capture individual differences in CD4 + T-cell decreases during ART interruptions and increases during ART reinitiations.
The results of this analysis are consistent with results from the SMART trial [3, 4] ; however, our results contrast with outcomes from several STI trials outside Africa that interrupted and reintroduced ART at higher CD4 + T-cell thresholds than SMART and Trivacan [29] [30] [31] [32] [33] . These studies found that when ART is interrupted at CD4 + T-cell counts >350 cells/µl (up to >700 cells/µl in the recent randomized controlled LOng Term Treatment Interruption [LOTTI] trial led by Maggiolo et al. [35] ) and reintroduced at CD4 + T-cell counts ≤350 cells/µl, reduced time spent at low CD4 + T-cell counts might eliminate differences in survival between STI and continuous ART. However, none of these studies had enough power to detect differences in morbidity and mortality rates, especially given their short duration. As illustrated in Figure 2 , STI strategies with interruption/reintroduction thresholds at CD4 + T-cell counts 500/350 cells/µl and 700/350 cells/µl might appear comparable to continuous ART in the short-run. Longer-term projections over patients' lifetimes, however, suggest that continuous ART is more effective than STI, even if ART is interrupted at CD4 + T-cell counts >700 cells/µl and reintroduced at <350 cells/µl. This finding is consistent with the results of a subgroup analysis in SMART showing that morbidity and mortality rates for STI and continuous ART were different, even at high CD4 + T-cell counts [9] . Results were most sensitive to ART-related toxicity rates and risk of resistance to ART, especially when patients started ART at higher CD4 + T-cell counts than currently recommended. When we assumed higher rates of fatal ART-related toxicity, STI produced results comparable to continuous ART in patients who interrupted/reintroduced ART at CD4 + T-cell counts 700/500 cells/µl. Although newer antiretroviral drugs associated with lower toxicity rates [36, 37] are rarely available in resource-limited countries, it is likely that low-cost but highly toxic drugs, such as stavudine, will soon be replaced with safer medications in these settings [27, 28, 38, 39] . Consequently, ART-related toxicity will decrease and the potential benefits of using STI to avoid toxicity will also decrease.
If we assumed a lower risk of resistance to ART during STI, then STI and continuous ART led to comparable outcomes when patients initiated ART at CD4 + T-cell counts >350 cells/µl and interrupted/reintroduced ART at CD4 + T-cell counts 700/500 cells/µl. This sensitivity analysis allowed us to evaluate the effect of potentially implementing STI with PI-based ART. In Trivacan, 93% of patients in the CD4 + T-cell-guided STI arm started ART with an NNRTI-based regimen, most often in combination with zidovudine and lamivudine [4] , NRTIs with differing half-lives. At interruption, NNRTIs were discontinued 5 days before NRTIs, but it is unclear whether this delay was enough to avoid resistance completely. Patients might have been on functional monotherapy for several days at the beginning of each interruption, which might have led to NNRTI resistance [20, [40] [41] [42] [43] . Recently, studies have shown that it is possible to reduce the probability of virological resistance after each interruption by replacing NNRTIs in first-line ART with a PI for a short time before interruption, because PIs have a shorter half-life and a higher genetic barrier to resistance [44] . If the risk of virological resistance to ART during STI decreases to below the risk of resistance during continuous ART, one goal of STI could be to reduce resistance to ART by decreasing exposure to drugs. Reductions in resistance would be particularly valuable in low-income settings, where often only two ART regimens are available. However, only three antiretroviral drug classes are available in these settings, and the risk of resistance on a secondline regimen that contains recycled drugs will likely be much lower if it contains drugs with high genetic barriers, such as PIs, than drugs with low genetic barriers, such as NNRTIs. In addition, NNRTIs are often preferred for first-line ART because they are much more affordable than PIs [45] . It is therefore unlikely that PIs will be recommended as first-line therapy in sub-Saharan Africa in the near future.
This analysis has several limitations. First, data on mean CD4 + T-cell count changes during interruption and reintroduction periods were from patients whose baseline characteristics corresponded to those in the Trivacan trial. We assumed that these changes would be similar at higher CD4 + T-cell counts. Furthermore, the data from the trial were collected over a 24-month period and a mean of two interruptions/reintroductions [4, 20] . CD4 + T-cell count decreases during ART interruptions and increases during ART reintroductions in Trivacan might therefore not be generalizable to patients with higher initial CD4 + T-cell counts or additional cycles of ART interruptions and reintroductions. For example, in the SMART trial, which followed patients for a mean time of 16 months, CD4 + T-cell counts decreased 87 cells/µl/month in the first 2 months of interruption and increased 166 cells/µl/month in the first 8 months of reinitiation [3] . In the BASTA trial, which interrupted ART at CD4 + T-cell counts >800 cells/µl and reintroduced ART at CD4 + T-cell counts <400 cells/µl, CD4 + T-cell count decreases during ART interruptions varied by nadir CD4 + T-cell count [30] . Second, patients in the STI strategy had an increased risk of non-AIDS diseases compared with patients on continuous ART, but only because their average CD4 + T-cell counts were lower and because they did not benefit from the independent protective effect of ART during interruptions. In sensitivity analysis, we further increased the risk of severe non-AIDS diseases in the STI group, particularly cardiovascular disease and malignancies, to twice that observed in SMART. The results remained stable to these variations. Third, we did not consider STI scenarios in which HIV RNA testing might be available. If it were, patients on STI would perhaps have had a longer life expectancy, as virological failure would have been detected earlier, especially during treatment interruptions. Fourth, there are no published data on the efficacy of continuous NNRTI-based ART after it has been used for STI. We derived estimates for decreased ART efficacy using data on the rates of virological resistance detected after each interruption in the fixed STI arm of Trivacan. We performed extensive sensitivity analyses on all of these parameters and found that they did not affect the main policy conclusions.
A randomized trial is ongoing in Côte d'Ivoire to evaluate the effect of ART initiation based on the 2006 WHO guidelines versus earlier initiation in HIVinfected patients [46] . If this trial shows that starting ART earlier is associated with better outcomes, ART initiation at higher CD4 + T-cell counts might become the standard of care. Although this policy could reduce morbidity and increase life expectancy, long term ARTrelated toxicity, drug fatigue, non-adherence and societal costs will increase. This model-based analysis demonstrates that STI could be comparable to continuous ART in Côte d'Ivoire if patients start ART with CD4 + T-cell counts >200 cells/µl, interrupt/reintroduce ART at CD4 + T-cell counts 700/500 cells/µl, and use drugs with higher genetic barriers such as PIs. If ongoing trials in Côte d'Ivoire and other resource-limited settings move treatment guidelines to earlier in the course of disease, then physicians and patients may become more interested in using STI at very high CD4 + T-cell interruption and reintroduction thresholds, when the risk of HIV-related disease events is low.
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